News New price gets Clovis’ PARP inhibitor on the CDF NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p
News Strong results for AZ’s Lynparza will help in PARP battle AstraZeneca has announced that its PARP inhibitor cancer treatment Lynparza has recorded strong results in a new phase 3 trial.<
News US pharma tariffs of up to 100% finalised by Trump Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
